Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) EBT (2016 - 2025)

Fate Therapeutics (FATE) has disclosed EBT for 14 consecutive years, with -$32.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 43.84% year-over-year to -$32.5 million, compared with a TTM value of -$136.7 million through Dec 2025, up 29.19%, and an annual FY2025 reading of -$136.7 million, up 29.19% over the prior year.
  • EBT was -$32.5 million for Q4 2025 at Fate Therapeutics, down from -$32.2 million in the prior quarter.
  • Across five years, EBT topped out at -$24.9 million in Q1 2023 and bottomed at -$84.6 million in Q3 2022.
  • Average EBT over 5 years is -$51.1 million, with a median of -$46.8 million recorded in 2023.
  • The sharpest move saw EBT tumbled 109.01% in 2021, then surged 66.38% in 2023.
  • Year by year, EBT stood at -$69.1 million in 2021, then grew by 10.92% to -$61.5 million in 2022, then rose by 29.05% to -$43.7 million in 2023, then crashed by 32.55% to -$57.9 million in 2024, then soared by 43.84% to -$32.5 million in 2025.
  • Business Quant data shows EBT for FATE at -$32.5 million in Q4 2025, -$32.2 million in Q3 2025, and -$34.0 million in Q2 2025.